A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers

• Status: Completed
• Trial end date: 2010-08-06
• Target enrollment: 0
• Participant gender: Male

Summary

The main purpose of this study is to assess the safety and pharmacokinetics of SRT2379 (25, 75, 250, 500, 1000, 2000, and 3000 mg/day [fasted] and 500 mg/day [fed]) in healthy male volunteers.

The purpose is also to explore the effect of SRT2379 on plasma concentrations of Fibroblast Growth Factor 21 (FGF21) and to identify other possible biomarkers suitable for future clinical assessment of oral SIRT1 activators.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Be male within the age range of 18 to 55 years.

• Voluntarily sign an Independent Review Board/Research Ethics Committee (IRB/REC)-approved informed consent form to participate in the study after all relevant aspects of the study have been explained and discussed with the subject.

• Have Hematology, Coagulation, Clinical Chemistry and Urinalysis test results that are within normal, allowable limits (if out-of-range, must be considered clinically significant by the Principal Investigator to be exclusionary) and performed within 21 days of receiving first dose of test material. In addition, the Principal Investigator will discuss any out-of-range electrolyte values with Sirtris' medical monitor for assessment of clinical significance.

• Have a BMI (Body Mass Index) ≥18.0 and ≤30.0 kg/m^2.

• Be clear of any history of HIV 1 and 2 and hepatitis B and C.

• Have no significant disease or clinically significant abnormal laboratory value as deemed by the Investigator on the laboratory evaluations, medical history, or physical exam.

• Have a normal 12-lead ECG or an ECG with abnormality considered to be clinically insignificant. Specifically, the QTcB must be ≤ 450 msec, and no evidence of bundle branch block must be present.

• Have the ability to communicate with the investigative site staff in a manner sufficient to carry out all protocol procedures as described.

• Subject and his partner must agree to use an acceptable double barrier method for birth control from the Screening visit through 3 months after the last dose of test material.

Exclusion Criteria:

• Subject has had a major illness in the past three months or any significant ongoing chronic medical illness that the Investigator would deem unfavorable for enrollment.

• Subject has renal or liver impairment.

• Subject has clinically significant findings on Screening 24 hour 12-lead Holter.

• Subject has a history of gastro-intestinal surgery or has a current gastrointestinal disease which may influence drug absorption.

• Subject has a history, within 3 years, of drug abuse (including benzodiazepines, opioids, amphetamine, cocaine, and THC) or a positive drug result at Screening.

• Subject has a history of smoking, within 3 months, or is currently a smoker.

• Subject has a history of alcoholism, and/or is currently drinking more than three drinks per day on a regular basis [one drink is equal to one unit of alcohol (one glass of wine, half a pint of beer, one measure of a spirit)].

• Subject has participated in a clinical trial within the past three months.

• Subject has a history of difficulty in donating blood or accessibility of veins in left or right arm.

• Subject has donated blood (one unit or 350 mL) within three months prior to receiving test material.

• Subject is taking herbal and dietary supplements or prescription drug therapy for which 5 times the half-life is longer than 21 days (i.e., the Screening period) prior to enrollment into the study. Please note: subjects must refrain from taking herbal or dietary supplements for the duration of the study.

• Unwillingness or inability to follow the procedures outlined in the protocol.

• Subject is mentally or legally incapacitated.